Our Story
Why We Started OsNovum
Osteoporosis is one of the most common chronic conditions in the world—and yet, for millions, it remains one of the most overlooked. With few effective treatments and even fewer compassionate options, patients—especially women—are left to suffer silently, navigating a landscape of dangerous side effects and declining bone health.
OsNovum was born from a simple but powerful belief: strong bones shouldn’t come at the cost of systemic harm. We are here to change what’s possible for patients with weak and fragile bones. More importantly, we won’t stop until they have the safe, regenerative care they deserve.
From Maxillofacial to Musculoskeletal
We’re not starting from scratch.
OsNovum is powered by the same proprietary regenerative compound that has transformed bone regeneration in the jaw through our sister company, SteinerBio.
After decades of proven success, it was clear: this technology could do more.
Now, we’re expanding that proven science beyond dentistry to treat skeletal fragility with a solution designed to be applied directly to weakened bone, stimulating natural repair without systemic risks.
A New Paradigm in Bone Health
OsNovum’s technology isn’t another pill. It’s a localized, regenerative solution that speaks the body’s language—stimulating osteoblast activity and turning soft, poorly mineralized bone into healthy, dense tissue.
By targeting the specific areas most at risk, we eliminate the need for system-wide exposure, empowering the body to repair itself exactly where it’s needed. No medication. No severe side effects. Just science doing what it does best.
Science with a voice. Innovation with a mission.
Over 80% of osteoporosis patients are women.
And yet, most innovations in this space are driven by systems that overlook them. OsNovum is different.
Led by Roslynn Steiner, a seasoned leader with executive vision, we’re proud to be a female-led company with a bold mission: to create a better future for patients through compassionate, scientifically sound innovation.
“We’re not just regenerating bone. We’re generating a movement.”
— Roslynn Steiner
Shaping the Future of Skeletal Health.
Our next steps are as ambitious as our mission:
- Finalizing our FDA De Novo submission
- Building the first OsNovum clinics to bring this solution to patients
- Expanding access to regenerative care for millions
Our crowdfunding efforts brought together over 200 investors and raised more than $339,000—fully funding our next step toward FDA submission. We’re grateful for every voice, dollar, and ounce of belief that got us here.
As we move through this next phase of navigating FDA clearance and into building, testing, ad commercialization, our commitment will only grows stronger.
Follow our progress as we bring this innovation to life.
PROUD MEMBER OF:
Tissue Engineering and Regenerative Medicine International Society (TERMIS)
American Society for Bone and Mineral Research (ASBMR)